Small Molecule Supply Chain Resilience

Empowering pharmaceutical companies to reduce disruption impact and unlock improved margins through strategic biopharmaceutical insight.

Start your risk assessment

Our Value Proposition

Why enhanced biopharmaceutical understanding matters for your portfolio.

Reduce Impact

Small molecule API supply chains are uniquely vulnerable. With our insight you can minimise disruptions and protect revenue.

5–8% revenue protected

Unlock Margins

Leverage competitive tension through strategic API supplier management to unlock improved margins and strengthen your position.

60–75% faster recovery

Reduce Risk

Cut supply chain vulnerability by implementing science‑based risk assessments and proactive mitigation strategies.

35–60% lower vulnerability

Protect Market Share

Maintain market share during disruptions while competitors face prolonged supply chain challenges.

Market position maintained

Hidden Risks in Pharma Supply Chains

BCS Class II compounds are especially vulnerable. Here’s why.

Low solubility & high permeability

Complex formulation requirements make rapid supplier changes difficult and time consuming.

Manufacturing sensitivity

Heightened sensitivity to manufacturing variability leads to increased regulatory scrutiny.

Bioequivalence barriers

Complex bioequivalence requirements create significant barriers to rapid supplier changes.

Decorative background
Class IHigh solubility
High permeability
Class IILow solubility
High permeability
Class IIIHigh solubility
Low permeability
Class IVLow solubility
Low permeability

Higher Losses

BCS Class II disruptions cause 2–3× greater revenue loss due to complex reformulation and extended timelines.

Diversification Challenges

67% require revalidation (12–24 months) when changes are needed, delaying supply restoration.

Regulatory Heterogeneity

ASEAN nations have divergent bioequivalence requirements, causing 15–25% permanent market erosion.

Seizing Opportunities in a Vulnerable Market

Three converging forces are creating unprecedented vulnerability in pharmaceutical supply chains.

Geopolitical
Regulatory
Formulation
1

Geopolitical volatility

Rising trade tensions and supply restrictions are impacting critical APIs and finished products. 4+ changes announced on US tariffs on Chinese/Indian API in 2025.

2

Formulation complexity

BCS Class II APIs have increasingly complex formulation requirements; 75% of new chemical entities are BCS Class II with high API sensitivity.

3

Regulatory divergence

ASEAN markets have differing bioequivalence requirements, causing delays and increasing costs when qualifying new suppliers.

How We Can Add Value

Strategic advisory and technical capability‑building delivered by industry experts with 60+ years’ experience.

Biopharmaceutical Analysis Strategic API Supplier Management Supply Chain Risk Assessment

Enhanced Resilience

Significantly reduce supply chain disruption impact and restoration time through improved biopharmaceutical understanding.

Regulatory Predictability

Navigate the complex regulatory landscape with confidence through our expertise in divergent bioequivalence requirements.

Competitive Advantage

Maintain market share during disruptions while competitors face prolonged supply chain challenges.

Is Your Current Portfolio at Risk?

Identify vulnerabilities and explore how Greengates Bio can help you build resilience in ASEAN markets.

  • Comprehensive BCS Class II vulnerability analysis
  • API supplier diversification strategy
  • ASEAN regulatory harmonization roadmap
Request Your Assessment

Talk to Our Experts

We’re here to help you reduce risk and grow value. Send us a message and we’ll get back to you soon.